Phase 2 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women between 18 and 75 years of age
- People whose general health and ability to carry out daily activities meets a specific medical standard (known as ECOG performance status 0–1 — confirm with trial site for what this means in practice)
- People whose menopausal status meets the trial's requirements (confirm specific menopausal criteria with trial site)
- People whose cancer has shown signs of getting worse on scans during or after their most recent cancer treatment
- People who have at least one area of cancer that can be measured on a scan, located outside the brain, meeting specific size and imaging standards
- People whose expected survival is greater than 3 months, as assessed by the treating doctor
- Women who could become pregnant must agree to use highly effective contraception during treatment and for 6 months after treatment ends, must have a negative pregnancy blood test within 7 days before joining, and must not be breastfeeding
- People who are willing and able to attend all study visits and follow study procedures, and who have signed a consent form agreeing to take part
Who may not be able to join:
- People who have cancer that has spread to internal organs in a way that is causing symptoms, where the treating doctor judges that hormone-based therapy would not be appropriate
- People with a history of serious heart or blood vessel disease
- People whose heart trace (ECG) results show abnormalities
- People with clinically significant abnormalities of the uterine lining, including conditions such as endometrial hyperplasia or abnormal uterine bleeding
- People who have an active infection or active tuberculosis requiring medication at the time of joining
- People who have had surgery, chemotherapy, immunotherapy, or certain targeted treatments within 4 weeks before starting the trial
- Women who are pregnant, breastfeeding, or planning to become pregnant during the study
- People with a known history of significant neurological or psychiatric conditions, or a history of misusing psychotropic substances or drugs
- People who are expected to need other cancer treatments or medications during the course of this trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86-0518-82342973
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose-limiting toxicity (DLT); Maximum tolerated dose (MTD); Recommended phase II dose (RP2D); Adverse events (AEs); Serious adverse events (SAEs); Objective response rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.